| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8531790 | Journal of the American Pharmacists Association | 2018 | 5 Pages |
Abstract
The current maximum allowable cost-based reimbursement system often results in inadequate payment for generic prescription drugs. The amount of underpayment varies substantially by payer and therapeutic class.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Logan Murry, Brandon Gerleman, Benjamin Urick, Julie Urmie,